The Kell antigen system (also known as Kell-Cellano system) is a group of antigens on the human red blood cell surface which are important determinants of blood type and are targets for autoimmune or alloimmune diseases which destroy red blood cells. The Kell antigens are peptides found within the kell protein, a 93 kilodalton transmembrane zinc-dependent endopeptidase which is responsible for cleaving endothelin-3.^[1][2]

There are several alleles of the gene which creates Kell protein. Two such alleles, K₁ (Kell) and K₂ (Cellano), are the most common. The kell protein is tightly bound to a second protein, XK, by a disulfide bond. Absence of the XK protein (such as through genetic deletion), leads to marked reduction of the Kell antigens on the red blood cell surface. Absence of the Kell protein (K₀), however, does not affect the XK protein.^[3]

The Kell protein has also recently been designated CD238 (cluster of differentiation 238).

Disease association

Kell antigens are important in transfusion medicine, autoimmune hemolytic anemia, and hemolytic disease of the newborn. Individuals lacking a specific Kell antigen may develop antibodies against Kell antigens when transfused with blood containing that antigen. Subsequent blood transfusions may be marked by destruction of the new cells by these antibodies, a process known as hemolysis. People without Kell antigens(K₀), must be transfused with blood from donors who are also K₀ to prevent hemolysis.

Autoimmune hemolytic anemia (AIHA) occurs when the body produces an antibody against a blood group antigen on its own red blood cells. The antibodies lead to destruction of the red blood cells with resulting anemia. Similarly, a pregnant woman may develop antibodies against fetal red blood cells, resulting in destruction, anemia, and hydrops fetalis in a process known as hemolytic disease of the newborn (HDN). Both AIHA and HDN may be severe when caused by anti-Kell antibodies,^[4] as they are the most immunogenic antigens after those of the ABO and Rhesus blood group systems.

McLeod phenotype

McLeod phenotype (or McLeod syndrome) is an X-linked anomaly of the Kell blood group system in which Kell antigens are poorly detected by laboratory tests. The McLeod gene encodes the XK protein, a protein with structural characteristics of a membrane transport protein but an unknown function. The XK appears to be required for proper synthesis or presentation of the Kell antigens on the red blood cell surface.

History

The Kell group was named after the first patient described with antibodies to K₁, a pregnant woman named Mrs. Kellacher in 1945.^[5] Mrs. Cellano was likewise a pregnant woman with the first described antibodies to K₂. The K₀ phenotype was first described in 1957 and the McLeod phenotype was found in Hugh McLeod, a Harvard dental student, in 1961.^[6][7]

Other associations

Evidence supports a genetic link between the Kell blood group (on chromosome 7 q33) and the ability to taste phenylthiocarbamide, or PTC, a bitter-tasting thiourea compound.^[8][9] Bitter taste receptor proteins in the taste buds of the tongue that recognise PTC are encoded on nearby chromosome locus 7 q35-6.

References

External links

• - OMIM entry for Kell protein
• - OMIM entry for XK protein
• Kell at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH

lt:Kell antigenas